Share this video  

SABCS 2022 | Gene expression profiling of breast cancer brain mets shows enrichment for non-luminal subtypes

Gaia Griguolo, MD, Istituto Oncologico Veneto, Padua, Italy, provides an overview of an investigation into gene expression profiling of patients with breast cancer brain metastasis. 65 archival samples of patients with breast cancer brain metastasis were investigated and more than 700 genes were profiled and intrinsic molecular subtyping was determined using the previously reported PAM50 subtype predictor. Median overall-survival from neurosurgery (OS) was calculated and the correlations between expression of each gene/PAM50 signature, breast cancer subtype and OS were studied. There was a high prevalence of non-luminal subtypes (basal-like and HER2-enriched) and low proportion of luminal-A and luminal-B subtypes. This was also true for HR+/HER2- brain metastasis, whereby more than half of the samples were non-luminal. Moreover, the basal-like signature by PAM50 was associated with worse prognosis overall. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.